Crinetics Pharmaceuticals (CRNX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec3

Crinetics Pharmaceuticals Begins Phase 1/2 Clinical Trial for CRN09682

13:01

Nov20

Crinetics Pharmaceuticals Launches Phase 3 Clinical Trial for Paltusotine

21:05

Nov10

Cantor Fitzgerald analyst reiterates buy rating on Crinetics Pharmaceuticals

16:48

Nov7

Analyst Maintains Buy Rating on Crinetics Pharmaceuticals

11:56

Crinetics Pharmaceuticals released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 143 K (forecast USD 394 K), actual EPS USD -1.3807 (forecast USD -1.254)

00:00

Crinetics Pharmaceuticals released FY2025 9 Months earnings on November 6 After-Market EST, actual revenue USD 1.535 M, actual EPS USD -3.6531

00:00

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 143 K, Net Income -130.09 M, EPS -1.3807

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 1.031 M, Net Income -115.64 M, EPS -1.2329

May8

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 361 K, Net Income -96.77 M, EPS -1.0394

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change